Rades Dirk, Dziggel Liesa, Schild Steven E
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
In Vivo. 2018 Jul-Aug;32(4):825-828. doi: 10.21873/invivo.11314.
BACKGROUND/AIM: Personalization of the treatment of brain metastases considering patient's overall survival (OS) prognosis is gaining importance. This study was conducted to develop an OS score particularly for patients receiving local therapies for single brain metastasis from gynecological malignancies.
In 11 patients, the following factors were retrospectively analyzed for associations with OS: Age, Karnofsky performance score (KPS), tumor type, extra-cranial metastatic sites, and time from diagnosis of gynecological malignancy to treatment of brain metastasis. Factors showing at least a strong trend were used for the score.
A KPS of 80-90% resulted in a significantly better OS than a KPS of 50-70% (p=0.008). Absence of extra-cranial metastases showed a strong trend (p=0.052). For the score, the following points were used: KPS 50-70%=0, KPS 80-90%=1, presence of extra-cranial metastatic sites=0, absence=1. Patients' scores were 0, 1 or 2 points. OS rates at both 6 and 12 months were 0%, 67% and 100%, respectively (p=0.020).
This specific score can be used to estimate OS in patients receiving local therapies for single brain metastasis from gynecological malignancies and personalize their care.
背景/目的：考虑患者总生存期（OS）预后的脑转移瘤治疗个性化正变得越来越重要。本研究旨在开发一种专门针对接受妇科恶性肿瘤单发脑转移瘤局部治疗患者的OS评分。
对11例患者的以下因素进行回顾性分析，以探讨其与OS的相关性：年龄、卡氏功能状态评分（KPS）、肿瘤类型、颅外转移部位以及从妇科恶性肿瘤诊断到脑转移瘤治疗的时间。显示至少有强烈趋势的因素用于评分。
KPS为80 - 90%的患者OS明显优于KPS为50 - 70%的患者（p = 0.008）。无颅外转移显示出强烈趋势（p = 0.052）。评分采用以下标准：KPS 50 - 70% = 0分，KPS 80 - 90% = 1分，存在颅外转移部位 = 0分，不存在 = 1分。患者得分0、1或2分。6个月和12个月时的OS率分别为0%、67%和100%（p = 0.020）。
该特定评分可用于估计接受妇科恶性肿瘤单发脑转移瘤局部治疗患者的OS，并实现其护理的个性化。
